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p73 is one of the tumor-suppressor p53 family of nuclear transcription factor. As expected from the structural similarity between
p53 and p73, p73 has a tumor-suppressive function. However, p73 was rarely mutated in human primary tumors. Under normal
physiological conditions, p73 is kept at an extremely low level to allow cells normal growth. In response to a certain subset of
DNA damages, p73 is induced dramatically and transactivates an overlapping set of p53-target genes implicated in the promotion
of cell cycle arrest and/or apoptotic cell death. Cells undergo cell cycle arrest and/or apoptotic cell death depending on the type
and strength of DNA damages. p73 is regulated largely through the posttranslational modiﬁcations such as phosphorylation and
acetylation.Thesechemicalmodiﬁcationsaretightlylinkedtodirectprotein-proteininteractions.Inthepresentpaper,theauthors
describe the functional signiﬁcance of the protein-protein interactions in the regulation of proapoptotic p73.
1.Introduction
For a long time, p53 has been believed to be a solitary
gene. This classical point of view has been challenged by a
discovery of novel human p53 homologues termed p73 and
p63[1–3].Thus,p53familyiscomposedofp53,p73andp63.
p73 contains an NH2-terminal transactivation domain (TA;
amino acid residues 1–54), a central core sequence-speciﬁc
DNA-binding domain (DB; amino acid residues 131–310),
an oligomerization domain (OD; amino acid residues 345–
380)andaCOOH-terminalsterileαmotif(SAM;aminoacid
residues484–549)domain[1].Amongthem,thecentralcore
sequence-speciﬁc DNA-binding domain is highly conserved
(more than 60% amino acid sequence identity) across the
family, and p53 lacks the COOH-terminal SAM domain
which is involved in the protein-protein interaction [4]. As
expectedfromthestructuralsimilarity betweenp53andp73,
p73 has an ability to transactivate an overlapping set of p53-
target genes implicated in cell cycle arrest and/or apoptotic
cell death such as p21WAF1, MDM2, BAX, PUMA, and NOXA
[5–7]. Indeed, forced expression of p73 induced cell cycle
arrest and/or apoptotic cell death in certain cancerous cells
[1, 8, 9].
Since p73 was mapped at human chromosome 1p36.3
where genomic aberrations are frequently observed in a
variety of tumors [10–14], it is likely that p73 could be
one of the classical Knudson-type tumor-suppressor genes.
To address this issue, the extensive mutation search for p73
was carried out. In a sharp contrast to p53 bearing loss
of-function mutations in 50% of human tumors [15, 16],
p73 was rarely mutated in human tumors [17], suggesting
that p73 is not a Knudson-type tumor-suppressor gene. In
support with these results, initial genetic studies revealed
that p73-deﬁcient mice do not develop spontaneous tumors
[18]. p53-deﬁcient mice underwent spontaneous tumor
development, mainly sarcomas and lymphomas [19]. Of
note, Flores et al. demonstrated that p73 is required for p53-
dependent apoptotic cell death, indicating that p73 is one of
the essential coactivators for p53, and these observations also
emphasized the functional importance of p73 in the regula-
tion of DNA damage-induced p53-dependent proapoptotic
pathway [20]. Subsequent genetic studies revealed that mice
harboring hemizygous p73 develop spontaneous tumors,
and their spectrum is quite diﬀerent from that of p53-
deﬁcient mice [21]. Based on these results, p73 has been2 International Journal of Proteomics
considered to be one of the critical tumor-suppressors,
although p73 was infrequently mutated in human primary
tumors.
Extensive expression studies demonstrated that p73
encodes at least seven alternative splicing variants with
diﬀerent COOH termini (p73α,p 7 3 β,p 7 3 γ,p 7 3 δ,p 7 3 ε,
p73η, and p73ξ), termed the TA variants [1, 22–24]. Since
these splicing variants contain the intact NH2-terminal
transactivation domain, they have the varied transcriptional
potential. Until now, each TA variant-speciﬁc biological
function remains unclear. In addition to COOH-terminal
splicing variants, p73 produced NH2-terminally truncated
forms of p73 termed the ΔNp73 variants (Δp73α, Δp73β,
Δp73γ, Δp73δ, Δp73ε, Δp73η,a n dΔp73ξ) arising from
the alternative promoter usage [25]. ΔNp73 lacked NH2-
terminal transactivation domain and had an oncogenic
potential [26, 27]. Indeed, higher expression levels of ΔNp73
were strongly correlated with poor prognostic outcome in
neuroblastoma patients [28]. In a good agreement with
these observations, ΔNp73 was frequently overexpressed
in a variety of human tumor tissues as compared with
their corresponding normal tissues [29]. Of note, ΔNp73
displayed a dominant-negative behavior toward TAp73 as
well as wild-type p53 [25]. Furthermore, TAp73 was also
inhibited by mutantformsofp53 [30].Intriguingly, Liuet al.
reportedthatΔNp73βhasanabilitytoinducecellcyclearrest
and apoptotic cell death in association with the upregulation
of p53-target genes [31]. Unlike ΔNp73β, ΔNp73α was
inactive in suppressing cell growth. This complicated issue
should be addressed further.
Under normal physiological conditions, steady-state
expression of p73 is maintained at quite low level and
thereby keeping this dangerous proapoptotic protein in an
inactive form [7]. Initial studies showed that p73 is not
induced in response to DNA damage such as actinomycin
D treatment and UV exposure [1]. However, subsequent
studies demonstrated that p73 is induced and activated in
response to a certain subset of DNA damaging agents [32].
Accumulated evidence strongly suggests that DNA damage-
mediated induction and activation of p73 is regulated
by posttranslational modiﬁcations such as phosphorylation
and acetylation, which is tightly linked to protein-protein
interactions [5–7].
In the present paper, we describe the regulatory mecha-
nisms of proapoptotic p73 through protein-protein interac-
tions.
2. Negative AutoregulatoryFeedbackLoop
As described in [25], ΔNp73 acts as a dominant-negative
inhibitor toward wild-type p73. Since ΔNp73 had an onco-
genicpotential[26,27],thebalancebetweentheintracellular
expression levels of proapoptotic wild-type p73 and anti-
apoptotic ΔNp73 plays a critical role in the regulation of cell-
fate determination. We and others found that wild-type p73
hasanabilitytotransactivateitsdominant-negativeinhibitor
ΔNp73 [29, 33, 34], and thereby creating a feedback control
loop which tightly regulates the proapoptotic function of
DNA damage
p73
p73
p73
ΔNp73
ΔNp73
ΔNp73
Apoptosis Oncogenesis
Figure 1: Dominant-negative eﬀect of ΔNp73 on wild-type p73.
In response to DNA damage, wild-type p73 transactivates its
dominant-negative inhibitor ΔNp73. The intracellular balance
between the expression levels of wild-type p73 and ΔNp73 is a
critical determinant of cell fate.
wild-type p73 (Figure 1). Since ΔNp73 retains an intact
central core sequence-speciﬁc DNA-binding domain as well
as an oligomerization domain, it is likely that ΔNp73 inhibits
wild-type p73 by direct protein-protein interaction between
them through the oligomerization domain (defective hetero-
oligomer formation) and/or the dominant-negative compe-
tition for DNA-binding sites with wild-type p73 [5, 35].
Thus, ΔNp73 contributes to a safety system preventing
inappropriate cell death.
Maisse et al. demonstrated that ΔNp73 is rapidly
degraded in response to DNA damage [36]. Although the
precise molecular mechanisms behind the selective degrada-
tion of ΔNp73 in response to DNA damage remains elusive,
this preferential degradation of ΔNp73 might relieve the
inhibitory eﬀect of ΔNp73 on wild-type p73, and results in
the promotion of cell cycle arrest and/or apoptotic cell death
of damaged cells. Recently, Sayan et al. found that the RING
ﬁngerdomainubiquitinproteinligasetermedPIR2isadirect
p73-target gene product, and PIR2 preferentially promotes
the proteasomal degradation of ΔNp73 [37]. Based on their
results, PIR2 expression was induced upon DNA damage
in association with a signiﬁcant accumulation of wild-
type p73. In addition, a strong interaction between ΔNp73
and PIR2 was detectable, whereas wild-type p73 bound to
PIR2 with a much lower aﬃnity. Therefore, the preferential
degradation of ΔNp73 mediated by PIR2 might be due to
diﬀerential binding aﬃnity of PIR2 to ΔNp73 and wild-type
p73.
Previously, Ohtsuka et al., described that p73 directly
transactivates cyclin G [38]. According to their results, cyclin
G bound to p73 and promoted its proteolytic degradation
in a ubiquitination-independent manner. Although the pre-
cise molecular mechanisms underlying cyclin G-dependent
proteolytic degradation remains unclear, there could exist
a negative feedback control pathway in which cyclin G
regulates the stability of p73.International Journal of Proteomics 3
3. Proteolytic Degradation of p73
Under normal physiological conditions, p73 is kept at an
extremely low level. Since proteasome inhibitor treatment
resulted in a signiﬁcant accumulation of the endoge-
nous p73 [39], p73 is regulated at least in part in a
ubiquitin/proteasome-dependent manner. MDM2 which
targets p53 for ubiquitin/proteasome-dependent degrada-
tion, bound to NH2-terminal transactivation domain of
p73 but did not promote its degradation even though
MDM2 inhibited p73-mediated transcriptional as well as
proapoptotic activity [40–43]. It might be due to the fact
that p73 lacks the degradation signal located within amino
acid residues 92–112 of p53, which has been considered
to confer MDM2 degradability [44]. Rossi et al. employed
a phage display procedure to identify a novel p73-binding
partner [45]. After the several rounds of screening, they
found that HECT-type E3 ubiquitin protein ligase termed
Itch is associated with p73. According to their results, their
interaction was mediated by PY motif of p73 and WW
domain of Itch. Itch had an ability to ubiquitinate eﬃciently
p73 but not p53, and promoted its proteasome-dependent
degradation. Itch did not interact with p53, which lacks PY
motif. In contrast to p53, ΔNp73 was also the substrate
of Itch. Of note, Itch was rapidly reduced in response to
DNA damage through as yet unknown mechanisms, and
thereby allowing p73 to increase. Asher et al. described
that binding of YAP1 to PY motif of p73 prevents the
interaction between Itch and p73 to stabilize p73 [46].
Consistent with these observations, Levy et al. demonstrated
that YAP1 stabilizes p73 by displacing Itch binding to p73
[47]. Similarly, NEDD4-binding protein termed N4BP1 was
abletointerferethecomplexformationofItchwithp73[48].
N4BP1 had an undetectable eﬀect on the stability of Itch.
It appears to be important to clarify the molecular mech-
anisms behind DNA damage-induced downregulation of
Itch.
F-box protein termed FBXO45 contains NH2-terminal
F-box domain and SPRY domain. SPRY domain has been
shown to be involved in protein-protein interactions [49].
Recently, Peschiaroli et al. reported that FBXO45 promotes
the proteasome-dependent degradation of p73 [50]. Based
on their results, FBXO45 bound to p73. Their complex
formation was mediated by SAM domain of p73 and SPRY
domain of FBXO45. Forced expression of FBXO45 resulted
in a signiﬁcant reduction in expression level of p73. Treat-
ment of proteasome inhibitor rescued FBXO45-mediated
downregulation of p73, suggesting that p73 is degraded
by FBXO45 in a proteasome-dependent manner. Like Itch,
FBXO45 was capable to promote the ubiquitin/proteasome-
dependent degradation of wild-type p73 as well as ΔNp73.
Additionally, FBXO45 was down-regulated in response to
DNA damage. Zhang et al. demonstrated that one of PIAS
SUMO-ligase family members termed PIASy is associated
with p73 and PIASy-mediated sumoylation induces protea-
somal degradation of p73 [51]. PIASy signiﬁcantly reduced
p73-mediated transcriptional activation. Intriguingly, we
have found that HECT-type E3 ubiquitin protein ligase
termed NEDL2 has an ability to polyubiquitinate p73 and
increase its stability [52], indicating that polyubiquitination
of p73 does not always act as a degradation signal.
It has been shown that p73 is also regulated in a
proteasome-independentmanner[53].Forexample,Munar-
riz et al. revealed that calpain I is able to cleave p73 at
two distinct sites including NH2-terminal transactivation
domain and COOH-terminal oligomerization domain [54].
Consistent with these results, forced expression of the
endogenous calpain inhibitor termed calpastatin resulted in
an increase in the steady-state expression level of p73.
4. Phosphorylation-Dependent
Activationofp73
Like p53, multiple phosphorylations following DNA damage
regulate the stability as well as activity of p73 [5–7]. It has
beenshownthatDNAdamageactivatesnonreceptortyrosine
kinase c-Abl through ATM-dependent phosphorylation of
c-Abl at Ser-465 [55–59]. Initial studies demonstrated that
c-Abl is associated with p73 through SH3 domain of c-
Abl and PY motif of p73, and directly phosphorylates p73
at Tyr-99 in response to CDDP and ionizing radiation
[60–62]. Phosphorylated form of p73 underwent nuclear
redistributionandbecameassociatedwiththenuclearmatrix
[63]. c-Abl-mediated phosphorylation of p73 at Tyr-99
increased its stability and enhanced its transcriptional as
well as proapoptotic activity. It has been shown that c-Abl
stimulates the catalytic activity of p38 MAP kinase [64].
Sanchez-Prieto et al. found that c-Abl-mediated activation
of p38 MAP kinase leads to phosphorylation of Thr residues
adjacent to Pro residues of p73, and thereby increasing the
protein stability of p73 [65]. Mantovani et al. described that
COOH-terminal three amino acid residues including Ser-
412, Thr-442, and Thr-482 are the phosphorylation sites
mediated by p38 MAPK [66]. Previous studies showed that
DNA damage induces c-Abl-dependent phosphorylation of
PKCδ and promotes the nuclear translocation of PKCδ [67].
Ren et al. revealed that PKCδ catalytic fragment (PKCδCF)
interacts with NH2-terminal transactivation domain as well
as central core sequence-speciﬁc DNA-binding domain of
p73, and phosphorylates p73 at Ser-289 within central
core sequence-speciﬁc DNA-binding domain [68]. PKCδCF-
mediated phosphorylation of p73 increased the stability of
p73 and enhanced its transcriptional as well as proapoptotic
activity.
Chk1 and Chk2 have been shown to be the downstream
eﬀector kinases of ATM and ATR, which play a critical
role in the regulation of DNA damage response [69, 70].
Gonzalez et al. described that Chk1 interacts with p73
and phosphorylates p73 at Ser-47 in response to DNA
damage [71]. According to their results, Chk1 but not
Chk2 had an ability to phosphorylate p73. Chk1-mediated
phosphorylation enhanced p73-dependent transactivation
capacityaswellasproapoptoticfunction.Subsequentstudies
demonstrated that Chk1 and Chk2 are required for DNA
damage-induced accumulation of p73 [72]. Based on their
results, Chk1 and Chk2 contributed to the transcriptional4 International Journal of Proteomics
activation of p73 gene, which might be due to the stabi-
lization of E2F1 in response to DNA damage. As described
previously [73–75], E2F1 acts as a transcription factor for
p73.
It has been shown that c-Abl activates the JNK signaling
pathway in response to DNA damage, and JNK is closely
involved in the apoptotic response to a variety of genotoxic
stresses [56, 76, 77]. Recently, Jones et al. reported that
JNK has an ability to stabilize p73 in a phosphorylation-
dependent manner [78]. JNK was associated with p73 and
phosphorylated its multiple Ser and Thr residues including
Ser-8, Ser-97, Ser-110, Ser-333, Ser-412, Thr-442, and Thr-
482. JNK-mediated phosphorylation enhanced the tran-
scriptional as well as proapoptotic activity of p73.
Previously, we described that COOH-terminal Pro-rich
domain (amino acid residues 380–513) contains transacti-
vation ability as examined by GAL4 system [79]. Recently,
Nyman et al. precisely identiﬁed the COOH-terminal trans-
activation domain of p73 which exists within amino acid
residues 381 to 399 [80]. Intriguingly, this second COOH-
terminal transactivation domain preferentially regulated the
transcription of p53-target genes implicated in the induction
of cell cycle arrest rather than apoptotic cell death. PKC
phosphorylated p73 at Ser-388, and markedly enhanced
the transcriptional activity of p73. Mutation at Ser-388
resulted in a remarkable reduction of the p73-mediated
transcriptional activation. Taken together, their results indi-
cate that PKC-mediated phosophorylation of p73 at Ser-388
contributes to the selective induction of cell cycle arrest.
It has been well known that IKK (IκB kinase) complex
acts as an upstream regulator of prosurvival NF-κB signaling
pathway [81]. IKK complex is composed of three functional
subunitsincludingIKK-α,IKK-β,andIKK-γ.W eha v efound
that nuclear IKK-α is induced to accumulate in response to
DNA damage and associated with the central core sequence-
speciﬁc DNA-binding domain of p73 in nuclear matrix [82].
DNA damage-mediated nuclear accumulation of IKK-α was
dependent on phospho-ATM [83]. IKK-α had an ability
to stabilize p73 by inhibiting its polyubiquitination, and
enhanced p73-mediated transcriptional activation as well
as proapoptotic activity. In addition, IKK-α phosphorylated
the NH2-terminal portion of p73 and a kinase-deﬁcient
mutant form of IKK-α had undetectable eﬀect on p73.
Thus, IKK-α-mediated activation of p73 was regulated in a
phosphorylation-dependent manner (Figure 2).
5. Phosphorylation-Dependent
Inhibition of p73
Phosphorylation does not always act as an activation signal.
Irwin et al. described that expression of p73 is regulated in a
cell cycle-dependent manner [74]. Under their experimental
conditions, p73 started to increase at the end of G1 phase,
which was mediated by E2F1. Gaiddon et al. found that
p73 interacts with cyclin/CDK complex through its cyclin
recognition motif (CRM) [84]. p73 contains two CRM
sequences located at NH2-terminal portion (149-KKL-151)
and COOH-terminal region (515-RAL-517). Cyclin/CDK
DNA damage
ATM
P
P
P
IKK-α
p73
Apoptosis
Figure 2: p73-dependent apoptotic cell death in response to DNA
damage.UponDNAdamage,phospho-ATMphosphorylatesIKK-α
andpromotesnuclearaccumulationofIKK-α.IKK-αthenenhances
transcriptional as well as proapoptotic function of p73 in a p53-
independent manner.
complex phosphorylated p73 at Thr-86 and p73 was most
highly phosphorylated at Thr-86 in G2 as well as M phase.
From the functional point of view, cyclin/CDK-mediated
phosphorylation at Thr-86 reduced the transcriptional activ-
ity of p73. However, the biological signiﬁcance of phospho-
p73 in the regulation of cell cycle progression remains
unclear.
During the extensive search for p73-binding partners by
using a yeast-based two-hybrid screening procedure, we have
identiﬁed PKA catalytic subunit β (PKA-Cβ) as a novel p73-
binding protein [85]. p73 bound to PKA-Cβ in mammalian
cells through its NH2-terminal portion (amino acid residues
63–130) and COOH-terminal region (amino acid residues
469–636). In vitro kinase reactions revealed that PKA-Cβ is
able to phosphorylate NH2-terminal region of p73. Within
this region, there exists a putative PKA recognition site
(78-RAAS-82). Of note, PKA-Cβ inhibited p73-mediated
transcriptional activation as well as proapoptotic activity
following DNA damage in a phosphorylation-dependent
manner.
Hck is one of the nonreceptor tyrosine kinase Src
family [86–88]. Considering that Hck interacts with c-
Abl and their interaction modulates each other’s activity
[89], Paliwal et al. investigated the possible role of Hck
in the regulation of p73 [90]. According to their results,
Hck was associated with p73 through its SH3 domain, and
phosphorylated p73 at Tyr-28. Forced expression of Hck led
to the stabilization of cytoplasmic p73 but not of nuclear
p73 in a phosphorylation-dependent manner. Hck inhibited
p73-mediatedtranscriptionalaswellasproapoptoticactivity,International Journal of Proteomics 5
which required the intact SH3 domain of Hck, suggesting
that physical interaction between Hck and p73 plays an
important role in the inhibition of p73.
Plk (Polo-like kinase) family is composed of four
members including Plk1, Plk2, Plk3, and Plk4. Plk1 has
been considered to be a positive cell cycle regulator [91–
93], and also shown to be a negative regulator of p53
[94]. Recently, we have found for the ﬁrst time that Plk1
attenuates transcriptional as well as proapoptotic function
of p73 [53]. Based on our results, Plk1 was associated with
p73 through NH2-terminal domain of p73 and catalytic
domain of Plk1. Kinase-deﬁcient Plk1 had a marginal eﬀect
on p73. Indeed, in vitro kinase reactions demonstrated that
Plk1 phosphorylates p73 at Thr-27. Komatsu et al. revealed
that Plk1 also suppresses another p53 family member, p63,
through physical interaction and phosphorylation [95]. Plk1
phosphorylated p63 at Ser-52.
Plk3 has been shown to be closely involved in the regula-
tion of DNA damage response through the direct interaction
with p53 accompanied with an induction of its phosphoryla-
tionatSer-20[96,97].IncontrasttoPlk3/p53interaction,we
havedemonstratedthatPlk3isassociatedwithNH2-terminal
region of p73 and inhibits p73-mediated transacriptional
activation as well as proapoptotic activity [98]. In addition,
Plk3 decreased the stability of p73. Since kinase-deﬁcient
P l k 3h a da nu n d e t e c t a b l ee ﬀect on p73, Plk3-mediated
inhibition was regulated in a phosphorylation-dependent
manner. In fact, Plk3 was able to phosphorylate certain
amino acid residue(s) between 63 and 113 of p73. Thus, it
is likely that Plk3 attenuates the inappropriate p73-mediated
apoptotic cell death in response to DNA damage.
6. Acetylation-DependentRegulation of p73
Like p53, p73 is also regulated by p300-mediated acetylation.
Zeng et al. showed that histone acetyltransferase p300
binds to p73 through its NH2-terminal CH1 domain and
NH2-terminal transactivation domain of p73 [99]. p300
stimulated p73-mediated transcriptional activation as well
as proapoptotic function. Subsequent studies demonstrated
that p73 is acetylated by p300 at Lys-321, Lys-327 and Lys-
331 in response to DNA damage [100]. Furthermore, c-
Abl was required for DNA damage-mediated acetylation of
p73 and acetylated forms of p73 preferentially transactivated
p53-targetgenesimplicatedintheinductionofapoptoticcell
d e a t hs u c ha sp53AIP1. Mantovani et al. found that prolyl
isomerase Pin1 promotes the conformational change of p73,
and enhances proapoptotic activity of p73 [66]. Accord-
ing to their results, c-Abl enhanced the phosphorylation-
dependent interaction between Pin1 and p73, and thereby
inducing the acetylation of p73 mediated by p300. Indeed,
Pin1 greatly enhanced p73 acetylation by p300. In addition,
forced expression of p300 resulted in a remarkable stabi-
lization of p73. Strano et al. revealed that YAP1 promotes
p73/p300complexformationandpotentiatesp300-mediated
acetylation of p73 [101]. Therefore, it is likely that p300-
mediated acetylation of p73 reduces the ubiquitination
levels of p73 by competition between acetylation and
p73 p73 ASPP1 ASPP2
BAX BAX
Apoptosis Apoptosis
PUMA PUMA
Figure 3: p73/ASPP complex preferentially induces the expression
of proapoptotic BAX and PUMA. p73 forms a complex with ASPP1
or with ASPP2, and these transcriptional complexes selectively
transactivate proapoptotic p73-target genes such as BAX and
PUMA.
ubiquitination. In support with these observations, SIRT1
with an intrinsic deacetylase activity abrogatedp73 mediated
transacriptional activation and apoptotic cell death [102].
On the other hand, Zeng et al. demonstrated that p300 acts
as a coactivator of p73 without inducing its acetylation
[103]. Further studies should be required to address this
issue.
7.SubcellularLocalizationofp73
Subcellular localization is one of the critical determinants for
theactivityofp73.Kimetal.identiﬁedHIPK2asanovelp73-
binding partner by using yeast-based two-hybrid screening
[104]. HIPK2 has been shown to be Ser/Thr kinase which
phosphorylates p53 at Ser-46 and enhance proapoptotic
activity of p53 [105]. HIPK2 bound to p73 through its
COOH-terminal region containing PEST sequence and the
oligomerization domain of p73. Reporter assays revealed
that HIPK2 enhances the transcriptional activity of p73.
Intriguingly, HIPK2 colocalized with p73 in the nuclear
body, suggesting that nuclear structures such as nuclear
body might provide an important subnuclear locale for p73
function.
Previously, Kim et al. employed the yeast-based two-
hybrid procedure to identify a novel p73-binding pro-
tein [106]. After the extensive screening, they identiﬁed
amphiphysinIIb-1.AmphiphysinIIb-1whichcontainsNH2-
terminal BAR domain and COOH-terminal SH3 domain,
was one of the splicing variants of cytoplasmic amphiphysin
IIb [107]. According to their results, amphiphysin IIb-
1 interacted with p73 through its COOH-terminal SH3
domain and COOH-terminal region of p73 (amino acid
residues 321–376). This interaction signiﬁcantly inhibited
p73-mediated transacriptional activation and apoptotic cell
death. Subsequent studies demonstrated that amphiphysin
IIb-1 promotes the cytoplasmic relocalization of p73 by
masking the nuclear localization signal (NLS) of p73 (amino
acid residues 338–348).
WWOX gene is located at 16q23.2-24.1, a genomic
region with a high incidence of loss of heterozygosity6 International Journal of Proteomics
(LOH) and homozygous deletions [108]. Ectopic expression
of WWOX in breast cancer cells inhibited tumor growth
in vivo [109], indicating that WWOX might be a candi-
date tumor-suppressor. Since WWOX contains two WW
domains, Fabbri et al. performed the aﬃnity assays to search
for cellular proteins which could bind to WW domain of
WWOX [110]. Finally, they found that PY motif of p73
interacts with WW domain of WWOX. In contrast to p73,
WWOX failed to bind to p53 which lacks PY motif. Based
on their results, WWOX caused the redistribution of p73
from nuclear compartment to the cytoplasm and repressed
thetransactivationfunctionofp73.Ofnote,cytoplasmicp73
enhancedproapoptoticactivityofWWOXinatranscription-
independent manner. However, the precise molecular mech-
anisms behind the cytoplasmic p73-mediated activation of
WWOX remains obscure.
8. PositiveRegulation of p73 through
Protein-Protein Interaction
Protein-protein interaction is one of the central events in a
varietyofcellularbiologicalresponse.Inthisconnection,p73
is regulated by protein-protein interactions.
By using the extensive pull-down assays, Strano et al.
identiﬁed YAP1 as one of p73-binding proteins [111]. YAP1
was originally identiﬁed as an adaptor protein binding to
SH3 domain of the Yes proto-oncogene product belonging
to the Src family of protein tyrosine kinases. YAP1 bound
to PY motif of p73 through its WW domain. YAP1 was
not associated with p53. Introduction of the mutation into
PY motif of p73 abrogated the interaction between p73 and
YAP1, suggesting that structural integrity of PY motif is
necessary for the interaction with YAP1. Forced expression
of YAP1 enhanced transactivation ability of p73, indicating
that YAP1 acts as a coactivator for p73.
As described previously [112], ASPP1 and ASPP2
belonging to ASPP family, bound to the central core
sequence-speciﬁc DNA-binding domain of p53, and specif-
ically stimulated the transcription of p53-target genes impli-
catedintheinductionofapoptoticcelldeath.Bergamaschiet
al. examined the possible eﬀect of ASPP1 and ASPP2 on p73
[113].Accordingtotheirresults,ASPP1andASPP2wereable
to interact with p73, and selectively enhanced p73-mediated
transactivationofproapoptoticBAX,PIG3,andPUMAgenes
but not of p21WAF1 and MDM2 genes. Consistent with these
observations, ASPP1 and ASPP2 enhanced proapoptotic
function of p73 in response to DNA damage. It is likely that
ASPP1 and ASPP2 are closely involved in the regulation of
promoter selectivity of p73 (Figure 3).
Jeong et al. identiﬁed p19ras as a novel p73-binding
protein by using the yeast-based two-hybrid screening
[114]. p19ras is an alternative splicing variant of c-H-ras,
and lacks transforming potential [115]. Systematic deletion
analysis revealed that p19ras interacts with p73 DNA-binding
domain-containing region (amino acid residues 54–310). Of
note, p19ras remarkably disrupted the complex formation of
p73 with its negative regulator MDM2. As expected, p19ras
blocked MDM2-mediated transcriptional repression of p73
and led to the activation of p73.
Similarly, we have employed the yeast-based two-hybrid
screening to identify p73-binding proteins. After several
rounds of extensive screening, we have obtained MM1 and
RanBPM [116, 117]. MM1 has been shown to interact
with c-Myc and suppress its transactivation function [118].
MM1 bound to COOH-terminal region of p73 (amino
acid residues 551–636) in cell nucleus. In contrast to p73,
MM1 failed to interact with p53. Forced expression of MM1
resulted in an enhancement of p73-mediated transcriptional
as well as growth-suppressing activity. As expected, MM1
h a da nu n d e t e c t a b l ee ﬀect on p53. RanBPM was initially
identiﬁed as a cellular protein which interacts with Ran
nuclear-cytoplasmic transport protein [119, 120], and con-
tains the putative SPRY domain which might be involved
in protein-protein interactions. The region containing the
canonical SPRY domain of RanBPM was associated with
COOH-terminal region of p73 (amino acid residues 551–
636). Like MM1, RanBPM did not bind to p53. RanBPM
hadanabilitytostabilizep73byinhibitingitsubiquitination.
Finally, RanBPM enhanced transcriptional and proapoptotic
activities of p73.
9. Negative Regulation of p73 through
Protein-Protein Interactions
As described previously [121, 122], WT1 gene mapped
at human chromosome 11p13 has been considered to
be a candidate tumor-suppressor gene for Wilm’s tumor.
Subsequent studies demonstrated that WT1 contains zinc
ﬁnger domain and acts as a sequence-speciﬁc transcription
factor [123]. Scharnhorst et al. reported that WT1 interacts
with p73 through its zinc ﬁnger domain [124]. WT1 had a
negligible eﬀect on the stability of p73 but strongly inhibited
p73-mediated transcriptional activation.
Tax which is encoded by the human T-cell leukemia
virus type I (HTLV-I), has been shown to be HTLV-I-
associated malignant transformation [125, 126]. Indeed, Tax
induced tumorigenesis and leukemogenesis in mice [127].
Although Tax had an ability to stabilize p73, p73-mediated
transcriptional activation was signiﬁcantly inhibited by Tax
[128]. Since CBP with an intrinsic histone acetyl transferase
activity acts as transcriptional coactivator for Tax and p73
[99, 129], Tax-mediated repression of p73 might be due to
the competition between Tax and p73 for CBP. Thus, it is
likely that inactivation of p73 by Tax contributes to HTLV-I-
dependent leukemogenesis.
Hepatitis C virus (HCV) core protein has been shown to
modulate p53 [130, 131]. Alisi et al. found that HCV core
protein directly interacts with COOH-terminal portion of
p73(aminoacidresidues321–353)[132].Luciferasereporter
assays demonstrated that HCV core protein enhances the
p73-dependent luciferase activity driven by MDM2 pro-
moter, whereas p73-dependent transactivation of BAX is
signiﬁcantly inhibited by HCV core protein. Consistent with
these observations, HCV core protein almost completely
blocked the ability of p73 to reduce cell viability.International Journal of Proteomics 7
It has been shown that adenovirus E1B, SV40 large
T antigen and human papilloma virus E6 which inhibit
p53, do not interact with p73 and do not aﬀect p73
activity [133, 134]. Similarly, adenovirus E4orf6 protein
with oncogenic potential bound to COOH-terminal region
of p53 and inhibited transcriptional activity of p53 [135].
Higashino et al. reported that E4orf6 is also associated with
COOH-terminal region of p73 and blocks p73-mediated
transcriptional as well as proapoptotic activity [136]. Thus,
it is possible that E4orf6-mediated inhibition of p53 and
p73 is responsible for the enhanced tumorigenic potential of
adenovirus. Additionally, these ﬁndings suggest that only a
subset of viral oncoproteins interact with p73.
Nagatani et al. found that the CCAAT-binding transcrip-
tion factor CTF2 is overexpressed in CDDP-resistant cells,
suggesting that CTF2 is involved in the acquisition of drug-
resistant phenotype of tumor cells [137]. Subsequent studies
revealed that CTF2 interacts with central core sequence-
speciﬁc DNA-binding domain of p73 (amino acid residues
228–312) [138]. According to their results, CTF2 strongly
inhibited the sequence-speciﬁc DNA-binding activity of p73.
Therefore, it is likely that CTF2-dependent inhibition of p73
contribute to the acquisition of drug-resistant phenotype of
tumor cells.
Bcl-2 associated athanogene BAG-1 protected cells from
cellular stress-mediated apoptotic cell death [139–141]. In
accordance with these results, BAG-1 expression correlated
with important clinical parameters of certain tumors [142].
Wang et al. reported that BAG-1 is associated with p73
through its intact BAG domain, and strongly attenuates
transcriptional activity of p73 [143]. Knocking down of
the endogenous BAG-1 resulted in a reactivation of p73.
Additionally,BAG-1reducedthestabilityofp73.Collectively,
BAG-1-mediated inhibition of p73 might be one of the
molecular mechanisms by which BAG-1 interfered with
stress-induced apoptotic cell death.
TIP60 is a member of MYST family of histone acetyl-
transferase which is conserved from yeast to human [144].
It has been shown that TIP60 acts as a coactivator for p53 by
inhibiting MDM2-mediated proteolytic degradation of p53
[145]. TIP60-mediated acetylation of p53 at Lys-120 had a
critical role in the regulation of p53-dependent apoptotic
response [146, 147]. Recently, Kim et al. described that, in
contrast to p53, TIP60 strongly inhibits transcriptional as
well as proapoptotic function of p73 [148]. TIP60 formed a
ternarycomplexwithp73,whichwasbridgedbyMDM2.Itis
likely that TIP60 recruits MDM2onto p73 thereby inhibiting
the activity of p73.
It is worth noting that human tumor-derived p53
mutants strongly inhibit p73 [30]. As described previously
[149], forced expression of p53 mutant caused increased
chemoresistance to anticancer drugs, suggesting that mutant
p53 inactivates p73-induced apoptosis through the inter-
action with p73. Strano et al. found that mutant p53
interacts with p73 through its central core sequence-
speciﬁc DNA-binding domain and p73 region containing
central core sequence-speciﬁc DNA-binding domain and
oligomerization domain [150]. Consistent with the previous
p73 Mutant p53 p53
Figure 4: Dominant-negative behavior of mutant p53 toward wild-
type p73 and p53. Mutant form of p53 binds to wild-type p73 as
well as p53 and strongly inhibits their tumor suppressive function.
observations [30], This interaction markedly suppressed
transcriptional activity of p73. Since mutant p53 bound to
the oligomerization domain of p73, homotetramer forma-
tion of p73 might be blocked by mutant p53. Alternatively,
binding of mutant p53 to central core sequence-speciﬁc
DNA-binding domain of p73 might attenuate its binding to
p53/p73-responsiveelement.Sangetal.describedthatforced
expression of p73 induces apoptotic cell death in human
breast cancer-derived and chemo-resistant MDA-MB-436
cells bearing p53 mutation [151], indicating that the balance
betweentheintracellularexpressionlevelsofmutantp53and
p73 is a critical determinant of chemosensitivity.
10.FuturePerspective
As described in the present paper, a variety of cellular
and viral proteins are involved in the positive and negative
regulations of proapoptotic p73 through protein-protein
interactions. From the clinical point of view, over 50%
human tumors carry p53 mutations. In some cases, tumors
bearing p53 mutations displayed chemoresistant phenotype.
On the other hand, p73 was infrequently mutated in human
tumors. Therefore, it is quite important to clarify the precise
molecular mechanisms underlying p73-dependent apoptotic
pathway in response to DNA damage. Furthermore, mutant
p53 acts as a dominant-negative inhibitor toward p73 as
well as p53 (Figure 4). In this connection, development of
a novel strategy to overcome and/or eliminate the dominant-
negative eﬀect of mutant p53 on p73 and p53 is required for
the eﬀective treatment of tumors carrying p53 mutations.
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